OOIR: Observatory of International Research

Papers

(The H4-Index of Oncogene is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma	144
Aberrant NSUN2-mediated m5C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma	144
A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability	137
Targeting telomerase for cancer therapy	129
High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcin	126
Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations	125
The functional roles of TCA cycle metabolites in cancer	124
Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines	113
Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity	111
Multifaceted role of branched-chain amino acid metabolism in cancer	105
Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications	104
Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo	101
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence	98
Emerging role of bacterial extracellular vesicles in cancer	98
HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression	91
STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT–MET switch and cancer metastasis	86
Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1α positive feedback loop	83
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches	82
Counteracting CAR T cell dysfunction	81
FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis	80
Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer	77
Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma	77
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma	77
Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis	77
The next tier of EGFR resistance mutations in lung cancer	76

CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1	75
Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy	74
Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy	74
LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway	73
RETRACTED ARTICLE: Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1	72
Loss and revival of androgen receptor signaling in advanced prostate cancer	70
NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization	70
RETRACTED ARTICLE: MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer	69
Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1	67
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors	66
Partial EMT in head and neck cancer biology: a spectrum instead of a switch	65
Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance	65
Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression	62
Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer	60
LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1α	60
Oncogenic functions and therapeutic targeting of EphA2 in cancer	60
The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression	58
DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway	57
Nerve fibers in the tumor microenvironment in neurotropic cancer—pancreatic cancer and cholangiocarcinoma	57
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor	57
A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination	57
Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma	56
Pathomechanisms in schwannoma development and progression	56
The role of MET in chemotherapy resistance	56
Role of p38 MAP kinase in cancer stem cells and metastasis	56
VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk	55
METTL3-mediated m6A methylation of SPHK2 promotes gastric cancer progression by targeting KLF2	55
METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner	54
Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions	54
CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation	54